

Influence of vitamin D₃ deficiency and 1,25 dihydroxyvitamin D₃ on *de novo* insulin biosynthesis in the islets of the rat endocrine pancreas

P-M Bourlon, B Billaudel and A Faure-Dussert

Laboratoire d'Endocrinologie, Université Bordeaux I, Avenue des Facultés, 33405 Talence Cedex, France

(Requests for offprints should be addressed to B Billaudel)

Abstract

Because 1,25 dihydroxyvitamin D₃ (1,25(OH)₂D₃) is known to activate the biosynthesis of numerous proteins in various tissues, experiments were undertaken to compare the influence of 1,25(OH)₂D₃ *in vitro* on both the secretion and biosynthesis of insulin in islets of Langerhans from both 4-week vitamin D₃-deficient rats and normal rats. Islets were either incubated or perfused after a 6-h induction period in the presence of various concentrations of 1,25(OH)₂D₃ from 10⁻¹² M, which was inactive in controls, to 10⁻⁶ M. Experiments were performed in the presence of a non-labelled amino acid mixture, to favour protein synthesis. Tritiated tyrosine was added as tracer during glucose stimulation. The newly synthesised proteins, labelled with [³H]tyrosine, were extracted by an acid-alcohol method and separated by gel chromatography adapted for low-molecular-weight proteins. Even in the presence of the amino acid mixture, the insulin response of the islets to 16.7 mM glucose was decreased by vitamin D₃ deficiency and improved by 1,25(OH)₂D₃. This beneficial effect did not occur in basal conditions, but only during glucose stimulation, and was observed in both phases of

insulin release. Moreover, these effects disappeared in the presence of 5 × 10⁻⁴ M cycloheximide, a protein biosynthesis inhibitor. Islets from vitamin D₃-deficient rats exhibited a general decrease in the amount of *de novo* biosynthesised proteins and of [³H]tyrosine-labelled insulin and proinsulin fractions. A 6-h period of 1,25(OH)₂D₃ induction significantly improved the amount of *de novo* biosynthesised proteins, and particularly of newly synthesised insulin in response to a 2-h glucose stimulation. Calculation of the rate of conversion of newly synthesised proinsulin-like material to insulin as the [³H]insulin/[³H]proinsulin-like material ratio provided evidence for a dose-dependent increase, induced by 1,25(OH)₂D₃, that could exceed that of normal islets. These data support the hypothesis that 1,25(OH)₂D₃ *in vitro* not only facilitated the biosynthetic capacity of the β cell – which was highly induced during a 16.7-mM glucose stimulation, via a global activation of islets protein biosynthesis – but also produced an acceleration of the conversion of proinsulin to insulin.

Journal of Endocrinology (1999) **160**, 87–95

Introduction

Cases of vitamin D₃ deficiency result not only from a lack of exposure to sun in wintertime (Dawson-Hughes *et al.* 1997) or from particular modes of dress (Garabedian & Ben Mekhbi 1991), but also as a result of nutritional disorders induced by unbalanced diet (Gedik & Akalin 1986) or in diabetic patients (Raghuramulu *et al.* 1992, Boucher *et al.* 1995, Rudnicki & Molsted-Pedersen 1997). One of the vitamin D₃ metabolites, 1,25 dihydroxy vitamin D₃ (1,25(OH)₂D₃), is considered to be the main steroid that has a crucial role in calcium homeostasis (Anderson 1991), and is able to improve the deficits in glucose tolerance observed in association with some cases of vitamin D₃ deficiency (Gedik & Akalin 1986, Raghuramulu *et al.* 1992, Boucher *et al.* 1995, Rudnicki & Molsted-Pedersen 1997).

1,25(OH)₂D₃ is known to exert its influence on various tissues via both genomic and more rapid non-genomic mechanisms (reviewed in Walters 1992). As calcium has a crucial role in the release of insulin in response to glucose (Grotsky & Bennett 1966), most authors agree that 1,25(OH)₂D₃ could exert beneficial effects on the reduced insulin release caused by vitamin D₃ deficiency, mainly by an improvement of calcium handling by pancreatic islets (Billaudel *et al.* 1991); however, the respective roles of 1,25(OH)₂D₃ and calcium in this effect are still under discussion (Beaulieu *et al.* 1993, Chertow *et al.* 1983, Tanaka *et al.* 1986). In recent studies in vitamin D₃-deficient rats, we showed that a prior exposure to low extracellular calcium *in vitro* enhances the sensitivity of the β cell to the stimulatory influence of 1,25(OH)₂D₃ on insulin release, suggesting a predominant genomic influence (Faure-Dussert *et al.* 1997). Most of the cellular

actions of 1,25(OH)₂D₃ are mediated via the interaction of this secosteroid with the vitamin D₃ receptor, which is expressed and localised, not only in the classical target tissues such as intestine, kidney and bone, but also in many other tissues and cell lines not primarily connected with mineral metabolism, such as the endocrine pancreas (reviewed in Walters 1992). Certain characteristics of its mechanism of action are similar to those of steroid hormones: specific intracellular receptors facilitating nuclear uptake of 1,25(OH)₂D₃ (Pike 1985), binding to promoter sequences in the genome, causing up- or down-regulation of the transcription of various genes (Minghetti & Norman 1988), and mRNA production coding for several *de novo* synthesised proteins (Norman *et al.* 1982). Indeed, it has been shown that 1,25(OH)₂D₃ influences the biosynthesis of numerous proteins in various tissues (Verhaeghe *et al.* 1989, Brunner & De Boland 1990, Chang & Price 1991, Mouland & Hendy 1991).

Because, in the rat, the insulin response to glucose is impaired by vitamin D₃ deficiency and can be improved by 1,25(OH)₂D₃ both *in vivo* and *in vitro* (Norman *et al.* 1980, Clark *et al.* 1981, Chertow *et al.* 1983, Labriji-Mestaghanmi *et al.* 1988), we have examined the hypothesis of an effect of 1,25(OH)₂D₃ on biosynthesis of insulin by the β cells, in which 1,25(OH)₂D₃ receptors have been observed (Clark *et al.* 1980, Stumpf *et al.* 1981, Johnson *et al.* 1994). Indeed, this hypothesis was supported by some of our previous studies showing that a 6-h delay was necessary for the beneficial influence of 1,25(OH)₂D₃ on the release of insulin (Billaudel *et al.* 1990). Moreover, 1,25(OH)₂D₃ did not affect the basal insulin response, but affected exclusively the insulin response of β cells to a glucose stimulation (Billaudel *et al.* 1990), which engages both insulin exocytosis and insulin biosynthesis (Portha 1991). For these reasons, we have studied both the content and secretion of insulin by the islets after a 6-h induction period in the presence, or not, of various concentrations of 1,25(OH)₂D₃, paying particular attention to the amount of insulin newly synthesised during a glucose stimulation. Use of a labelled amino acid, [³H]tyrosine, enabled us to follow the production of *de novo* synthesised proteins, and in particular proinsulin and insulin fractions, which were separated by chromatography. We compared islets from normal rats with those from 4-week vitamin D₃-deficient rats.

Material and Methods

Animals

Experiments were run in parallel using two groups of Wistar rats (CREJ, Le Genest-Saint-Isle, France): normal rats and 4-week vitamin D₃-deficient (D₃-deficient) rats. All animals were housed in a dark room for the 8 weeks after birth and had free access to food and water. After weaning (3 weeks old), the group of normal rats received

a balanced diet (AO4, UAR, Epinay sur Orge, France) with carbohydrates (59.7% w/w), proteins (16% w/w) and lipids (3% w/w) and containing calcium (0.64% w/w), phosphate (0.64% w/w) and vitamin D₃ (2000 IU/kg), whereas D₃-deficient rats received a rachitogenic diet (US Biochemical Corporation, Cleveland, OH, USA) devoid of vitamin D, but containing low calcium (0.5% w/w) and low phosphate (0.3% w/w), for 4 weeks. The D₃-deficient rats exhibited rachitis and hypocalcaemia as verified in our previous studies (Labriji-Mestaghanmi *et al.* 1988, Bourlon *et al.* 1996).

Isolation of islets and 1,25(OH)₂D₃ induction

Pancreatic islets of Langerhans were isolated by the collagenase (Boehringer Co, Mannheim, Germany) method (Lacy & Kostianovsky 1967). Batches of 50 islets from either normal rats or D₃-deficient rats were used; those from the latter were divided into five groups for a 6-h period of induction in the presence of various concentrations of 1,25(OH)₂D₃. Cycloheximide (5×10^{-4} M, Sigma), a potent inhibitor of protein synthesis, was added to the incubation medium in a control experiment. Inductions were run for 6 h at 37 °C in Krebs–Ringer bicarbonate (KRB) medium with 0.5% bovine albumin (fraction V, RIA grade, Sigma) and 0.5 mM Ca²⁺, and gassed with 95% oxygen/5% carbon dioxide. This medium also contained various non-labelled amino acids (in mM: alanine 0.1, arginine 0.1, cysteine 0.05, histidine 0.05, isoleucine 0.2, leucine 0.2, lysine 0.2, methionine 0.05, threonine 0.2, tryptophan 0.02, tyrosine 0.1, valine 0.2). The medium was changed every 2 h, dividing the 6-h induction period into three incubation periods of 2 h each, in an attempt to limit the well known feedback inhibition exerted by insulin in a closed medium (Iversen & Miles 1971). Glucose was present in a concentration of 8.3 mM for the two first periods and 16.7 mM for the last incubation period, providing a strong specific stimulation of the biosynthesis of insulin compounds (proinsulin, split proinsulins, insulin) and proteins necessary for the secretion of insulin by the β cells of the islets.

In order to determine the level of *de novo* protein biosynthesis, during the last 2 h of induction (during the 16.7-mM glucose stimulation) the islets were incubated with radiolabelled L-[1,4-³H]tyrosine (1850 Gbq/mmol; Amersham, Amersham, UK). This amino acid is a useful marker because it is incorporated into proinsulin, but not into the carboxypeptide segment resulting from the proteolytic cleavage of proinsulin (Schuit *et al.* 1991). Thus [³H]tyrosine will be incorporated into proinsulin, split proinsulins, and insulin, each of them including four tyrosines. Islets were then rinsed twice with KRB medium containing 5 mM non-labelled tyrosine, to eliminate free radioactivity (not incorporated into protein). Islets were ready for the separation and determination of *de novo* biosynthesised proinsulin and insulin, or for insulin

release studies using static incubation experiments or dynamic perfusion experiments as previously described (Billaudel *et al.* 1990).

Separation of proteins

Extraction procedure After the period of 1,25(OH)₂D₃ induction and [³H]tyrosine labelling, islets were treated for 24 h at 5 °C with 100 µl ethanol–acid mixture (ethanol 74% v/v; distilled water 24·6% v/v; hydrochloric acid 1·4% v/v). Small peptides, such as insulin (6·5 kDa) or proinsulin (9 kDa), remain in the soluble supernatant fraction, whereas heavier peptides form precipitates (Best *et al.* 1969). The incorporation of the ³H radioactivity into the small proteins was measured on aliquots of the supernatant, after addition of scintillation liquid (Emulsifier safe, Packard, Rungis, France), using a Packard Tricarb spectrometer. Similarly, the radioactivity of the heavy proteins was measured on the precipitate. The calculation of the total amount of *de novo* synthesised radiolabelled proteins was obtained as the sum of these two values.

Separation of insulin material Insulin compounds were separated by a chromatographic method, which was more precise for low-molecular-weight proteins, rather than by electrophoresis, which is better adapted for higher-molecular-weight proteins. Aliquots of the soluble fraction, after extraction with ethanol–acid mixture, were placed on top of a gel chromatography column (Sephadex G50, Pharmacia, Sweden). Elution was performed with KRB buffer containing 0·5% albumin. Effluents were collected in 1-ml fractions in which the total anti-insulin immunoreactive material was assayed by RIA. Insulin RIA was performed using a charcoal–dextran method (Herbert *et al.* 1965), with rat insulin as standard (Novo, Paris, France). Measurements of the [³H]tyrosine radioactivity, corresponding only to newly synthesised materials, were also made on the same fractions, as described above. Calibration of the column was made using ¹²⁵I-radiolabelled proinsulin and insulin as standard. The elution profile showed that insulin was eluted from fraction 34 to fraction 45 of the effluents, with a maximal peak at fraction 38, and proinsulin-like material at fraction 30 (proinsulin and split proinsulins have equivalent molecular weights).

Total islet protein content was determined with islets in aqueous solution by the Bio Rad protein–dye binding technique (Bradford 1976).

Statistical analysis

Results are expressed as means ± S.E.M. The number of experiments performed on each occasion with islets from two normal rats and six D₃-deficient rats is given as *n*. Data were analysed by analysis of variance (ANOVA) using the




Figure 1 Influence of vitamin D₃ deficiency and 1,25(OH)₂D₃ *in vitro* on 50 islets. Insulin response to 16·7 mM glucose during a 2-h incubation following a 6-h pre-incubation, in the presence or not of 1,25(OH)₂D₃. (N), islets from normal rats; (-D), 4-weeks vitamin D₃-deficient rats, in the presence of a biologically inactive 10⁻¹² M concentration as control or an active 10⁻⁸ M concentration without or with a biosynthesis inhibitor, 5 × 10⁻⁴ M cycloheximide. Values are means ± S.E.M.; number of experiments is shown within the bars, in parentheses. ^a*P*<0·001 compared with N; ^b*P*<0·001 compared with (-D) control or 10⁻¹² M; ^c*P*<0·001 compared with 10⁻⁸ M group (Student's *t*-test).

Bonferroni/Dunn complementary test for a statistical significance of at least <0·05. Student's *t*-test for unpaired samples was used for comparison of two groups such as D₃-deficient and normal islets, using three levels of significance (<0·05, <0·01 and <0·001).

Results

Total insulin content of islets and global insulin secretion

Vitamin D₃ deficiency did not significantly affect the total protein content of 50 islets compared with that of normal rats (0·91 ± 0·08 µg/islet, *n*=10, compared with 1·01 ± 0·09 µg/islet, *n*=9, respectively). However, vitamin D₃ deficiency decreased the total insulin content of 50 islets compared with that of normal rats, expressed either as ng/islet (25·72 ± 3·5, *n*=10, compared with 44·92 ± 4·28, *n*=9, respectively; *P*<0·01) or as ng/µg of proteins (28·2 ± 1·5, *n*=10, compared with 44·47 ± 3·18, *n*=9, respectively; *P*<0·001).

The release of insulin in response to a 16·7 mM glucose stimulation was studied using groups of 50 islets incubated for 2 h in the presence or not of 1,25(OH)₂D₃, following a 6-h preincubation period that was performed in the presence or not of 1,25(OH)₂D₃ as an induction period. As shown in Fig. 1, the insulin response of islets from D₃-deficient rats was very much lower than that of normal islets (*P*<0·001). Islets from D₃-deficient rats did not show any variation in their insulin release after a 6-h pre-exposure to a 10⁻¹² M concentration of 1,25(OH)₂D₃,




Figure 2 Influence of vitamin D₃ deficiency and 1,25(OH)₂D₃ *in vitro*, on the kinetics of the insulin response to 16.7 mM glucose of 50 islets during a perfusion performed after a 6-h pre-incubation, both being performed in the presence or not of 1,25(OH)₂D₃. The perfusion design consisted of a 15-min basal (4.2 mM glucose) prestimulatory recovery period, followed by a 30-min (16.7 mM) glucose stimulation and a 15-min post-stimulatory recovery period returning to basal secretion. Islets from normal rats (■; *n*=6) or from vitamin D₃-deficient rats with 10⁻¹² M inactive 1,25(OH)₂D₃ as control (○; *n*=7) or with 10⁻⁸ M 1,25(OH)₂D₃ (●; *n*=9) or 10⁻⁸ M 1,25(OH)₂D₃ in the presence of 5 × 10⁻⁴ M cycloheximide (—; *n*=7). Values are means ± S.E.M. from *n* experiments.

which is considered not to be biologically active. In contrast, the most commonly used 10⁻⁸ M concentration improved their insulin response (*P*<0.001 compared with D₃-deficient islets). This enhancing effect of 10⁻⁸ M 1,25(OH)₂D₃ on the insulin response to 16.7 mM glucose disappeared (Fig. 1) in the presence of 5 × 10⁻⁴ M cycloheximide, a protein biosynthesis inhibitor.

To complement to these static measurements, a kinetic study was performed (Fig. 2), using islets in perfusion after the 6-h pre-incubation period. Islets from normal rats increased their insulin release at the beginning of the 16.7 mM glucose stimulation (*P*<0.001 compared with their own basal secretion) and exhibited the two well-described phases of insulin secretion: a rapid first peak and a longer lasting second phase, returning to basal levels of secretion when glucose stimulation was replaced by the

4.2 mM basal glucose concentration. To compare the various groups of islets, we evaluated the amplitude of their insulin response to glucose by comparison of the area under the insulin curves over their own basal secretion by planimetry, thus including both phases of insulin release (Billaudel *et al.* 1988, 1990). Islets from D₃-deficient rats, exposed to the 10⁻¹² M inactive 1,25(OH)₂D₃ concentration as control, presented a very low insulin response to glucose compared with that in normal islets (respective insulin curves areas: 0.99 ± 0.08 ng/min, *n*=7 and 5.46 ± 0.51 ng/min, *n*=6; *P*<0.01). After 1,25(OH)₂D₃ induction with a 10⁻⁸ M concentration, we observed an increase of the area under the insulin curve: 1.89 ± 0.19 ng/min, *n*=8; *P*<0.01 compared with the 10⁻¹² M control group). The addition of 5 × 10⁻⁴ M cycloheximide to 10⁻⁸ M 1,25(OH)₂D₃ suppressed the beneficial effect of 1,25(OH)₂D₃ during the 16.7 mM glucose stimulation. Both phases of insulin release were decreased by vitamin D₃ deficiency and improved by 10⁻⁸ M 1,25(OH)₂D₃. In contrast, basal insulin secretion, both before and after glucose stimulation, was not significantly affected, whatever the group of islets.

De novo biosynthesis studies

The glucose-induced incorporation of a labelled amino acid, [³H]tyrosine, into the total proteins from 50 islets was measured after a 6-h induction with or without 1,25(OH)₂D₃ (Table 1). The amount of these *de novo* synthesised labelled proteins was decreased by vitamin D₃ deficiency (*P*<0.001 for islets from D₃-deficient rats exposed to 10⁻¹² M inactive 1,25(OH)₂D₃ compared with normal islets), but improved by 1,25(OH)₂D₃. This beneficial influence of the various concentrations of 1,25(OH)₂D₃ was analysed in comparison with the D₃-deficient group using a 10⁻¹² M inactive concentration as control. This action of 1,25(OH)₂D₃ was not significant at a 10⁻¹⁰ M concentration, but was significant for 10⁻⁸ M and 10⁻⁶ M (*P*<0.05).

The incorporation of labelled tyrosine into small proteins (acid-alcohol soluble), including newly synthesised insulin and proinsulin-like material (proinsulin and split proinsulins), like that into total labelled proteins, was decreased by vitamin D₃ deficiency (*P*<0.001) and improved by 1,25(OH)₂D₃, with a maximal influence at concentrations of 10⁻⁸ M and 10⁻⁶ M (*P*<0.05; Table 1).

Insulin and proinsulin-like fractions studies

A chromatographic separation, performed after the glucose-induced incorporation of [³H]tyrosine into groups of 50 islets, allowed us to compare more specifically the insulin and proinsulin-like chromatography peaks. The study of the effluent medium allowed us to determine both the total anti-insulin immunoreactive material contained

Table 1 Influence of vitamin D₃ deficiency (–D) and 1,25(OH)₂D₃ on glucose-induced, newly synthesised islet proteins ([³H]tyrosine-labelled) separated by chromatography: study of insulin peak (Ins, fraction 38) and proinsulin-like peak (Plns, fraction 30). Various concentrations of 1,25(OH)₂D₃ were used, from 10^{–12} M inactive as control, to 10^{–6} M. Values are means ± S.E.M.; number of experiments is in parentheses

	N (9)	–D 10 ^{–12} M 1,25(OH) ₂ D ₃ (10)	–D 10 ^{–10} M 1,25(OH) ₂ D ₃ (6)	–D 10 ^{–8} M 1,25(OH) ₂ D ₃ (7)	–D 10 ^{–6} M 1,25(OH) ₂ D ₃ (6)
Total islets	1 155 000	530 800*	574 000	1 064 000†	1 019 000†
labelled proteins (d.p.m.)	± 86 000	± 56 900	± 64 000	± 120 000	± 82 000
Acid-alcohol-	244 400	117 800*	129 000	163 400†	169 400†
soluble proteins (d.p.m.)	± 8700	± 13 800	± 8000	± 8200	± 12 100
[³ H]-tyrosine-labelled					
parts (d.p.m.)					
[³ H]-Ins (fraction 38)	37 100	13 300*	15 500	27 600†	28 200†
	± 2200	± 1900	± 1300	± 1800	± 1900
[³ H]-Plns (fraction 30)	10 660	3690*	4280	6340†	5040
	± 460	± 820	± 540	± 840	± 400

**P*<0.001 compared with islets from normal rats (N) (Student's *t*-test); †*P*<0.05 compared with (–D) with 10^{–12} M 1,25(OH)₂D₃ as control (ANOVA with Bonferroni/Dunn complementary tests).

inside the islets (Fig. 3A), and the amount of newly synthesised [³H]tyrosine-labelled material, on the same islets (Fig. 3B). As verified by standards, fractions 38 and 30 were more specific to insulin and proinsulin-like material, respectively, but some other newly synthesised and heavier proteins were apparent just to the left of proinsulin (Fig. 3B). For these reasons, we studied insulin and proinsulin-like peaks, respectively, on fractions 38 and 30.

The analysis of the total immunoreactivity peak (fractions 38, Fig. 3A) showed that the insulin peak was strongly decreased by 4 weeks of vitamin D₃ deficiency (293.5 ± 26, *n*=10 compared with 507.9 ± 53.2 ng/ml, *n*=9 for normal islets; *P*<0.01). It was not significantly improved by a 6-h 1,25(OH)₂D₃ induction period, whatever the concentration of 1,25(OH)₂D₃: 10^{–10} M, 10^{–8} M or 10^{–6} M (respectively 348.8 ± 22.8, *n*=6; 355.3 ± 45.4, *n*=7; 346.0 ± 28.4 ng/ml, *n*=6). The total immunoreactive proinsulin-like peak (fraction 30, Fig. 3A) was not significantly modified by either vitamin D₃ deficiency (13.20 ± 1.76, *n*=10 compared with normal islets 13.00 ± 2.76 ng/ml, *n*=9) or the presence of 1,25(OH)₂D₃ in whatever concentration: 10^{–10} M, 10^{–8} M or 10^{–6} M (respectively 11.60 ± 3.28, *n*=6; 9.56 ± 1.80, *n*=7; 10.08 ± 2.00 ng/ml, *n*=6). However, this global immunoreactive insulin material was not very representative of the material newly synthesised in response to glucose. It corresponded to the large insulin stores present in islets, thus hindering the detection of the discrete variations induced by 1,25(OH)₂D₃ and glucose stimulation. Indeed, as is reported generally (Randle & Hales 1972), insulin release represented only about 10 percent/h/islet of the islet insulin content in perfusion and only 3 percent/h/islet in incubation in the present experiments, because of the feedback inhibition effect that

usually occurs in a closed medium. These data made us aware of the need for a finer and more specific [³H]labelling study of insulin newly synthesised in response to glucose stimulation at the end of 1,25(OH)₂D₃ induction.

The newly synthesised labelled insulin peak (Table 1, fraction 38) was strongly decreased by vitamin D₃ deficiency (*P*<0.001 compared with normal islets), and improved by 1,25(OH)₂D₃, with a maximal effect at 10^{–8} M and 10^{–6} M concentrations (*P*<0.05 compared with D₃-deficient control islets). In contrast, the [³H]tyrosine-labelled proinsulin-like peak (fraction 30) was decreased by vitamin D₃ deficiency (*P*<0.001 compared with normal islets), and improved by 1,25(OH)₂D₃, with a maximal effect at 10^{–8} M (*P*<0.05 compared with D₃-deficient control islets). A comparison of the [³H]tyrosine-labelled insulin/proinsulin peak ratios was made between each group of islets, as an index of the neoconversion of proinsulin to insulin (Fig. 4). This ratio was not significantly decreased by vitamin D₃ deficiency, but it showed a significant increase in the presence of 1,25(OH)₂D₃. The maximal effect was observed at 10^{–8} M and 10^{–6} M concentrations (*P*<0.05 compared with 10^{–12} M as control). This 1,25(OH)₂D₃-induced, dose-dependent increase in this ratio exceeded even that of normal islets, thus supporting the hypothesis of a 1,25(OH)₂D₃-induced acceleration of the conversion rate of the neosynthesised proinsulin to insulin during glucose stimulation.

Discussion

The hypothesis of an 1,25(OH)₂D₃-induced activation of insulin biosynthesis must be considered for several reasons. First, 1,25(OH)₂D₃ was able to increase the amount of




Figure 3 Influence of vitamin D₃ deficiency and 1,25(OH)₂D₃ *in vitro* on (A) the anti-insulin immunoreactive material (insulin peak (fraction 38) and proinsulin-like peak (fraction 30, insert) separated by chromatography), and on (B) labelled newly synthesised material from [³H]tyrosine incorporation into 50 islets during a 2-h 16.7 mM glucose stimulation, after a 6-h incubation with or without 1,25(OH)₂D₃ induction. Islets from normal rats (■; n=9) and from vitamin D₃-deficient rats in the presence of various concentrations of 1,25(OH)₂D₃: 10⁻¹² M inactive as control (○; n=10), 10⁻¹⁰ M (□; n=6), 10⁻⁸ M (●; n=7) or 10⁻⁶ M (▲; n=6). Values are means ± S.E.M. from *n* experiments.

preproinsulin mRNA in islets from vitamin D₃-deprived rats either 8 h or 24 h after intraperitoneal injection (Ozono *et al.* 1990). Secondly, the beneficial effect of




Figure 4 Influence of vitamin D₃ deficiency and 1,25(OH)₂D₃ *in vitro* on the ratio of [³H]tyrosine-labelled insulin/proinsulin-like peaks as an index of the neoconversion of proinsulin to insulin. N, islets from normal rats; (-D), islets from vitamin D₃-deficient rats in the presence of concentrations of 1,25(OH)₂D₃ from 10⁻¹² M inactive as control, to 10⁻⁶ M. Values are means ± S.E.M. from *n* experiments. **P* < 0.05 compared with N; #*P* < 0.05 compared with (-D) 10⁻¹² M 1,25(OH)₂D₃ as controls (ANOVA with Bonferroni/Dunn complementary test).

1,25(OH)₂D₃ on insulin release was observed only in islets in which β cells were stimulated by glucose, but not under basal conditions (Taylor *et al.* 1988, Billaudel *et al.* 1990). Similarly, other authors have observed stimulatory effects of 1,25(OH)₂D₃ exclusively in pair-fed vitamin D₃-deficient rats, but not in fasted rats (Ozono *et al.* 1990), suggesting a better adaptation of the β cell to glucose, its preferential stimulus, which is able to activate insulin exocytosis and insulin biosynthesis. Finally, 1,25(OH)₂D₃ requires a delay to activate the β cell insulin response to glucose: this varies from 3 h to 20 h *in vivo* (Ishida *et al.* 1983, Kadowaki & Norman 1985, Cade & Norman 1987, Ozono *et al.* 1990) and after a 6-h induction *in vitro* (Billaudel *et al.* 1990) or after a 48-h culture (Taylor *et al.* 1988), but not directly *in vitro* from 0 to 4 h (Chertow *et al.* 1983, Taylor *et al.* 1988, Billaudel *et al.* 1990). To our knowledge, there exist few data on the influence of vitamin D₃ deficiency or on the effect of 1,25(OH)₂D₃ on insulin biosynthesis. The divergence in existing results is probably due to the differing experimental conditions used: no effect on insulin biosynthesis *in vitro* in 48-h cultured islets from mice (Taylor *et al.* 1988), but an *in vivo* activation of preproinsulin mRNA in islets from fed rats (Ozono *et al.* 1990).

In our present experimental conditions, islets were preincubated in the presence of an amino acid mixture during a 6-h 1,25(OH)₂D₃ induction and during the incubation or perfusion experiments, to favour insulin biosynthesis. We showed that, even in the presence of a supplementation of amino acid *in vitro*, islets from vitamin

D₃-deficient rats presented an altered insulin response to glucose, whereas their basal secretion was not significantly affected. In contrast, we confirmed that, even in the presence of amino acids, a 6-h 1,25(OH)₂D₃ induction could selectively improve the release of insulin from islets during glucose stimulation. Both phases of insulin response were facilitated: the first rapid phase, believed to reflect insulin exocytosis, and the second, longer lasting phase that is more dependent upon insulin biosynthesis (Portha 1991). It was indeed this second phase that was found to be the more reduced by vitamin D₃ deficiency in another study (Chertow *et al.* 1983). This second phase was the first to be increased by 3 days of vitamin D₃ repletion *in vivo*, whereas both phases of insulin release were increased after a longer time (6 days) of treatment (Billaudel *et al.* 1988). *In vitro*, we previously found that both phases of insulin response to glucose were activated after 6 h of 1,25(OH)₂D₃ induction, but neither of them at shorter times (<6 h) (Billaudel *et al.* 1990). In the present experimental conditions, the presence of amino acids and the 6-h 1,25(OH)₂D₃ induction period may have induced the biosynthesis of numerous proteins implicated either in exocytosis mechanisms or in the preparation of the β cell for insulin biosynthesis activation. Indeed, the ability of 1,25(OH)₂D₃ to induce an activation of insulin secretion in response to glucose was blocked by cycloheximide, supporting the hypothesis that the synthesis of new proteins was required for these mechanisms.

Conversely, certain of our results support the hypothesis that vitamin D₃ deficiency exerts its deleterious influence on islets of Langerhans via a progressive and long-term alteration of the processes of synthesis of the proteins necessary for the β cell insulin response to glucose. (1) The global total protein content of islets was not significantly affected by 4 weeks of vitamin D₃ deficiency, in agreement with results of previous experiments performed later, at week 5 (Labrijn-Mestaghami *et al.* 1988), whereas, during glucose stimulation, newly synthesised islet proteins (labelled by [³H]tyrosine incorporation) were already decreased by 4 weeks of vitamin D₃ deficiency. (2) The total insulin content of islets from 4-week vitamin D₃-deficient rats was already decreased at 4 weeks (as was also the case at 5 weeks), but not at 3 weeks of vitamin D₃ deficiency (Labrijn-Mestaghami *et al.* 1988). (3) After 4 weeks of vitamin D₃ deficiency, a parallel decrease was observed in the labelled alcohol-acid-soluble small proteins containing the *de novo* synthesised insulin and proinsulin-like material. (4) A more specific chromatographic study of islets confirmed that 4-week vitamin D₃ deficiency decreased the biosynthesis of insulin (total immunoreactive insulin or its labelled part alone, newly synthesised during glucose stimulation).

However, a period of only 6 h of 1,25(OH)₂D₃ induction, applied to islets from vitamin D₃ deficient rats, improved the insulin biosynthesis of islets, even though it did not completely restore (within 6 h) the deleterious

influence of 4 weeks of vitamin D₃ deficiency. The maximal effect was obtained in the presence of a 10⁻⁸ M concentration of 1,25(OH)₂D₃, which is precisely the concentration used most commonly by numerous authors. Indeed, 1,25(OH)₂D₃ increased the amount of newly synthesised proteins that were labelled during glucose stimulation. This was the case both for global proteins of the islets and for the alcohol-acid-soluble part containing new insulin and proinsulin material. This is the first demonstration of a beneficial influence of a 6-h 1,25(OH)₂D₃ induction on the *de novo* biosynthesis of labelled insulin and proinsulin-like material separated by column chromatography.

Finally, the present results provide evidence in support of the idea that 1,25(OH)₂D₃ exerted its beneficial effect on β cells by a particular activation of insulin turnover, accelerating the neoconversion of proinsulin to insulin. This hypothesis was supported by the complementary study of the [³H]tyrosine-labelled insulin/proinsulin ratio (proinsulin including split proinsulins), in which 1,25(OH)₂D₃ increased the ratio in a dose-dependent manner, showing that the newly synthesised insulin appeared more rapidly, with a conversion rate exceeding that of islets from normal rats. Such an acceleration of the neoconversion of proinsulin to insulin has previously been observed in our laboratory, with another steroid, 17- β -oestradiol (Faure *et al.* 1986).

In conclusion, the present data demonstrated that 1,25(OH)₂D₃ could activate the *de novo* biosynthesis of insulin in islets from vitamin D₃-deficient rats during the intense stimulation of the islets by a glucose stimulus, and could, in particular, increase the rate of conversion of proinsulin to insulin. We could not establish whether this acceleration of the conversion of proinsulin to insulin was a direct or an indirect effect, as this step was previously reported to be calcium-dependent (Steiner *et al.* 1996). All the present experiments were performed *in vitro* in the presence of 0.5 M extracellular calcium in the medium. Other authors reported that calcium can induce the transcription of certain genes in other tissues (Jackson & Bancroft 1988, Sheng *et al.* 1988). However, in recent studies we showed that, *in vitro*, calcium deprivation of islets from vitamin D₃-deficient rats rendered then more competent in mobilising intracellular calcium, for a better adaptation of the insulin response to glucose (Faure-Dussert *et al.* 1997). Further experiments are needed to study other proteins with larger molecular weights using the electrophoresis method. Indeed, some authors have reported that 1,25(OH)₂D₃ can increase translocation of protein kinase C to the nucleus and the modulation of gene expression in the kidney (Simboli-Campbell *et al.* 1992). This observation is in accord with our previous work in which we showed that 1,25(OH)₂D₃ can activate the protein kinase C and inositol triphosphate pathways in islets from vitamin D₃-deficient rats with a shorter delay (<45 min) (Billaudel *et al.* 1993, 1995), thus preceding its

effect on calcium handling at 4 h and on the insulin response to glucose after a 6-h 1,25(OH)₂D₃ induction (Billaudel *et al.* 1990, 1993).

Acknowledgements

We thank Novo Laboratories (Paris & Copenhagen) for providing rat insulin, Drs Kaiser and Fisher (Hoffman-LaRoche, Basel, Switzerland) for their generous gift of 1,25(OH)₂D₃, and Dr T Durkin for correcting the English. This study was supported by grants from Fondation pour la Recherche Médicale and Conseil Régional d'Aquitaine.

References

- Anderson JJB 1991 Nutritional biochemistry of calcium and phosphorus. *Journal of Nutrition and Biochemistry* **2** 300–307.
- Beaulieu C, Kestekian R, Havrankova J & Gascon-Barré M 1993 Calcium is essential in normalizing intolerance to glucose that accompanies vitamin D depletion *in vivo*. *Diabetes* **42** 35–43.
- Best CH, Haist RE & Ridout JH 1969 Diet and insulin content of pancreas. *Journal of Physiology* **97** 107–119.
- Billaudel B, Labrijj-Mestaghanmi H, Sutter BCJ & Malaisse WJ 1988 Vitamin D and pancreatic islet function. II. Dynamics of insulin release and cationic fluxes. *Journal of Endocrinological Investigation* **11** 585–593.
- Billaudel BJL, Faure AG & Sutter BCJ 1990 Effect of 1,25 dihydroxyvitamin D₃ on isolated islets from vitamin D₃-deprived rats. *American Journal of Physiology* **258** E643–E648.
- Billaudel B, Delbancut A, Sutter B & Faure A 1991 Mechanism of action of 1,25-dihydroxy-vitamin D₃ on islet insulin secretion from D₃ deficient rats. In *Vitamin D: gene regulation, structure-function analysis, and clinical application*, pp 337–338. Eds AW Norman, R Bouillon & M Thomasset. Berlin, New York: W de Gruyter.
- Billaudel BJL, Delbancut PA, Sutter BCJ & Faure AG 1993 Stimulatory effect of 1,25-dihydroxyvitamin D₃ on calcium handling and insulin secretion by islets from vitamin D₃-deficient rats. *Steroids* **58** 335–341.
- Billaudel BJL, Bourlon P-MD, Sutter BCJ & Faure-Dussert A 1995 Regulatory role of 1,25-dihydroxyvitamin D₃ on insulin release and calcium handling via the phospholipid pathway in islets from vitamin D-deficient rats. *Journal of Endocrinological Investigation* **18** 673–682.
- Boucher BJ, Mannan N, Noonan K, Hales CN & Evans SJW 1995 Glucose intolerance and impairment of insulin secretion in relation to vitamin D deficiency in East London Asians. *Diabetologia* **38** 1239–1245.
- Bourlon P-M, Faure-Dussert A, Billaudel B, Tramu G, Sutter B & Thomasset M 1996 Interrelationship between calbindins in A and B cells of the rat endocrine pancreas and insulin or glucagon secretion: influence of vitamin D₃ deficiency and 1,25-dihydroxyvitamin D₃. *Journal of Endocrinology* **148** 223–232.
- Bradford MM 1976 A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. *Analytical Biochemistry* **72** 248–254.
- Brunner A & De Boland AR 1990 1,25-Dihydroxyvitamin D₃ affects the synthesis, phosphorylation and *in vitro* calmodulin binding of myoblast cytoskeletal proteins. *Zeitschrift für Naturforschung* **45** 1156–1160.
- Cade C & Norman AW 1987 Rapid normalization/stimulation by 1,25-dihydroxyvitamin D₃ of insulin secretion and glucose tolerance in the vitamin D-deficient rat. *Endocrinology* **120** 1490–1497.
- Chang PL & Price CW 1991 1- α ,25-Dihydroxyvitamin D₃ stimulates synthesis and secretion of nonphosphorylated osteopontin (secreted phosphoprotein 1) in mouse JB6 epidermal cells. *Cancer Research* **51** 2144–2150.
- Chertow BS, Sivitz WI, Baranetsky NG, Clark SA, Waite A & Deluca HF 1983 Cellular mechanisms of insulin release: the effects of vitamin D deficiency and repletion on rat insulin secretion. *Endocrinology* **113** 1511–1517.
- Clark SA, Stumpf WE, Sar M, Deluca HF & Tanaka Y 1980 Target cells for 1,25-dihydroxyvitamin D₃ in the pancreas. *Cellular Tissue Research* **209** 515–520.
- Clark SA, Stumpf WE & Sar M 1981 Effect of 1,25-dihydroxyvitamin D₃ on insulin secretion. *Diabetes* **30** 382–386.
- Dawson-Hughes B, Harris SS & Dallal GE 1997 Plasma calcidiol, season, and serum parathyroid hormone concentrations in healthy elderly men and women. *American Journal of Clinical Nutrition* **65** 67–71.
- Faure A, Aerts L, Haouari M, Sutter BCJ & VanAssche FA 1986 Direct and indirect influence of a 14 days oestradiol-17 β treatment on the endocrine pancreas of the female rat. *Diabète et Métabolisme* **12** 137–142.
- Faure-Dussert AG, Delbancut APA & Billaudel BJL 1997 Low extracellular calcium enhances β cell sensitivity to the stimulatory influence of 1,25-dihydroxyvitamin D₃ on insulin release by islets from vitamin D₃-deficient rats. *Steroids* **62** 554–562.
- Garabedian M & Beu Mekhbi H 1991 Is vitamin-D-deficiency rickets a public health problem in France and Algeria? In *Rickets*, vol 21, pp 215–221. Nestle Nutrition Workshop Series Nestle Ltd. New York: Vevey/Raven Press Ltd.
- Gedik O & Akalin S 1986 Effects of vitamin D deficiency and repletion on insulin and glucagon secretion in man. *Diabetologia* **29** 142–145.
- Grodsky GM & Bennett LL 1966 Cation requirement for insulin secretion in the isolated perfused pancreas. *Diabetes* **15** 910–913.
- Herbert V, Lau KS, Gottlieb CW & Bleicher SJ 1965 Coated charcoal immunoassay of insulin. *Journal of Clinical Endocrinology* **25** 1375–1384.
- Ishida H, Seino Y, Seino S, Tsuda K, Takemura J, Nishi S, Ishizuka S & Imura H 1983 Effect of 1,25-dihydroxyvitamin D₃ on pancreatic B and D cell function. *Life Science* **33** 1779–1786.
- Iversen J & Miles DW 1971 Evidence of a feedback inhibition of insulin on insulin secretion in the isolated perfused canine pancreas. *Diabetes* **20** 1–9.
- Jackson AE & Bancroft C 1988 Proximal upstream flanking sequences direct calcium regulation of the rat prolactin gene. *Molecular Endocrinology* **2** 1139–1144.
- Johnson JA, Grande JP, Roche PC & Kumar R 1994 Immuno-histochemical localization for the 1,25(OH)₂D₃ receptor and calbindin D_{28k} in human and rat pancreas. *American Journal of Physiology* **267** E356–E360.
- Kadowaki S & Norman AW 1985 Time course study of the insulin secretion after 1,25-dihydroxyvitamin D₃ administration. *Endocrinology* **117** 1765–1771.
- Labrijj-Mestaghanmi H, Billaudel B, Garnier B, Malaisse WJ & Sutter BCJ 1988 Vitamin D and pancreatic islet function: I. Time course for changes in insulin secretion and content during vitamin D deprivation and repletion. *Journal of Endocrinological Investigation* **11** 577–584.
- Lacy PE & Kostianovsky M 1967 Method for the isolation of intact islets of Langerhans from pancreas. *Diabetes* **16** 35–39.
- Minghetti PP & Norman AW 1988 1,25(OH)₂-vitamin D₃ receptors: gene regulation and genetic circuitry. *FASEB Journal* **2** 3043–3053.
- Moulard AJ & Hendy GN 1991 Regulation of synthesis and secretion of chromogranin-A by calcium and 1,25-dihydroxycholecalciferol in cultured bovine parathyroid cells. *Endocrinology* **128** 441–449.

- Norman A, Roth J & Orci L 1982 The vitamin D endocrine system: steroid metabolism, hormone receptors and biological response (calcium binding protein). *Endocrine Review* **3** 331–366.
- Norman AW, Frankel BJ, Heldt AM & Grodsky GM 1980 Vitamin D deficiency inhibits pancreatic secretion of insulin. *Science* **208** 823–825.
- Ozono K, Seino Y, Yano H, Yamaoka K & Seino Y 1990 1,25-dihydroxyvitamin D₃ enhances the effect of refeeding on steady state preproinsulin messenger ribonucleic acid levels in rats. *Endocrinology* **126** 2041–2045.
- Pike JW 1985 Intracellular receptors mediate the biologic action of 1,25-dihydroxyvitamin D₃. *Nutrition Review* **43** 161–168.
- Portha B 1991 Physiologie de la cellule B des îlots de Langerhans. *Médecine Sciences* **7** 212–225.
- Raghuramulu N, Raghunath M, Chandra S, Sahay KB & Gupta PC 1992 Vitamin D improves oral glucose tolerance and insulin secretion in human diabetes. *Journal of Clinical and Biochemical Nutrition* **13** 45–51.
- Randle PJ & Hales CN 1972 Endocrine pancreas. In: *Handbook of Physiology. Section 7: Endocrinologie*, vol 1, pp 219–235. Eds DF Steiner & N Freinkel. Washington DC: American Physiological Society.
- Rudnicki PM, Molsted-Pedersen L 1997 Effect of 1,25-dihydroxycholecalciferol on glucose metabolism in gestional diabetes mellitus. *Diabetologia* **40** 40–44.
- Schuit FC, Kiekens R & Pipeleers DG 1991 Measuring the balance between insulin synthesis and insulin release. *Biochemical and Biophysical Research Communications* **178** 1182–1187.
- Sheng M, Dougan ST, McFadden G & Greenberg ME 1988 Calcium and growth factors pathways of *c-fos* transcriptional activation require distinct upstream regulatory sequences. *Molecular and Cellular Biology* **8** 2787–2794.
- Simboli-Campbell M, Franks DJ & Welsh J 1992 1,25(OH)₂D₃ increases membrane associated protein kinase-C in Mdbk cells. *Cellular Signalling* **4** 99–109.
- Steiner S, Aicher L, Raymackers J, Meheus L, Esquer-Blasco R, Anderson NL & Cordier A 1996 Cyclosporine a decreases the protein level of the calcium-binding protein calbindin-D 28 kDa in rat kidney. *Biochemical Pharmacology* **51** 253–258.
- Stumpf WE, Sar M & De Luca HF 1981 Sites of action of 1,25(OH)₂ vitamin D₃ identified by thaw-mount autoradiography. In: *Hormone Control of Calcium Metabolism*, pp 222–229. Eds DV Cohn, R V Taladge & J Matthews. Amsterdam: Excerpta Medica.
- Tanaka Y, Seino Y, Ishida M, Yamaoka K, Satomura K Yabuchi H, Seino Y & Imura H 1986 Effect of 1,25-dihydroxyvitamin D₃ on insulin secretion. Direct or mediated? *Endocrinology* **116** 1971–1976.
- Taylor KW, Lawrence E & Makin HLJ 1988 Insulin release from islets in tissue culture is increased after long-term incubation with 1,25-dihydroxyvitamin D₃. *Diabetologia* **31** 548A.
- Verhaeghe J, Suiker AMH, Nyomba BL, Visser WJ, Einhorn TA, Dequeker J & Bouillon R 1989 Bone mineral homeostasis in spontaneously diabetic BB rats. II – Impaired bone turnover and decreased osteocalcin synthesis. *Endocrinology* **124** 573–582.
- Walters MR 1992 Newly identified actions of the vitamin D endocrine system. *Endocrine Review* **13** 719–764.

Received 20 February 1998

Revised manuscript received 26 June 1998

Accepted 4 September 1998